Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Unknown 3Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2OTHER_GOV 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Gynecologic 1Dermatologic 1

Conditions

Neoplasms 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Nevi and Melanomas 1Neoplasms, Unknown Primary 1Melanoma 1Genetic Predisposition to Disease 1Disease 1Breast Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Sequence Analysis, RNA × Clear all
NCT07366008 2026-01-26

NorCUP

Haukeland University Hospital

Phase NA Not yet recruiting
350 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT04620278 2026-01-06

Genetic Investigation of Cancer Predisposition

The University of Texas Health Science Center at San Antonio

Not yet recruiting
100 enrolled

Disease, Neoplasms, Genetic Predisposition to Disease

NCT06605417 2025-02-27

NevustoMel

Fundacion Clinic per a la Recerca Biomédica

Recruiting
100 enrolled
Dermatologic

Melanoma, Nevi and Melanomas

NCT04846933 2025-01-16

DECIDER

Turku University Hospital

Phase NA Recruiting
200 enrolled
Gynecologic

Ovarian Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Fudan University

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03521245 2021-09-14

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

OmicsWay Corp.

Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03724097 2021-09-14

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

OmicsWay Corp.

Unknown
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡